Initial experience with the Cardiva Boomerang™ vascular closure device in diagnostic catherization

Brendan J. Doyle, Michael J. Godfrey, Ryan J. Lennon, James L. Ryan, John F. Bresnahan, Charanjit S. Rihal, Henry H. Ting

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objectives: The authors studied the safety and efficacy of the Cardiva Boomerang™ vascular closure device in patients undergoing diagnostic cardiac catheterization. Background: Conventional vascular closure devices (sutures, collagen plugs, or metal clips) have been associated with catastrophic complications including arterial occlusion and foreign body infections; furthermore, they cannot be utilized in patients with peripheral vascular disease or vascular access site in a vessel other than the common femoral artery. The Cardiva Boomerang™ device facilitates vascular hemostasis without leaving any foreign body behind at the access site, can be used in peripheral vascular disease, and can be used in vessels other than the common femoral artery. Methods: A total of 96 patients undergoing transfemoral diagnostic cardiac catheterization were included in this study, including 25 (26%) patients with contraindications to conventional closure devices. Femoral angiography was performed prior to deployment of the Cardiva Boomerang™ closure device. Patients were ambulated at 1 hr after hemostasis was achieved. Results: The device was successfully deployed and hemostasis achieved with the device alone in 95 (99%) patients. The device failed to deploy in 1 (1%) patient and required conversion to standard manual compression. Minor complications were observed in 5 (5%) patients. No patients experienced major complications including femoral hematoma > 4 cm, red blood cell transfusion, retroperitoneal bleed, arteriovenous fistula, pseudoaneurysm, infection, arterial occlusion, or vascular surgery. Conclusions: The Cardiva Boomerang™ device is safe and effective in patients undergoing diagnostic cardiac catheterization using the transfemoral approach, facilitating early ambulation with low rates of vascular complications.

Original languageEnglish (US)
Pages (from-to)203-208
Number of pages6
JournalCatheterization and Cardiovascular Interventions
Volume69
Issue number2
DOIs
StatePublished - Feb 1 2007

Fingerprint

Equipment and Supplies
Blood Vessels
Cardiac Catheterization
Hemostasis
Peripheral Vascular Diseases
Femoral Artery
Thigh
Foreign Bodies
Vascular Closure Devices
Erythrocyte Transfusion
Early Ambulation
False Aneurysm
Arteriovenous Fistula
Infection
Surgical Instruments
Hematoma
Sutures
Angiography
Collagen
Metals

Keywords

  • Cardiac catheterization
  • Closure device
  • Vascular access

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Doyle, B. J., Godfrey, M. J., Lennon, R. J., Ryan, J. L., Bresnahan, J. F., Rihal, C. S., & Ting, H. H. (2007). Initial experience with the Cardiva Boomerang™ vascular closure device in diagnostic catherization. Catheterization and Cardiovascular Interventions, 69(2), 203-208. https://doi.org/10.1002/ccd.20937

Initial experience with the Cardiva Boomerang™ vascular closure device in diagnostic catherization. / Doyle, Brendan J.; Godfrey, Michael J.; Lennon, Ryan J.; Ryan, James L.; Bresnahan, John F.; Rihal, Charanjit S.; Ting, Henry H.

In: Catheterization and Cardiovascular Interventions, Vol. 69, No. 2, 01.02.2007, p. 203-208.

Research output: Contribution to journalArticle

Doyle, BJ, Godfrey, MJ, Lennon, RJ, Ryan, JL, Bresnahan, JF, Rihal, CS & Ting, HH 2007, 'Initial experience with the Cardiva Boomerang™ vascular closure device in diagnostic catherization', Catheterization and Cardiovascular Interventions, vol. 69, no. 2, pp. 203-208. https://doi.org/10.1002/ccd.20937
Doyle, Brendan J. ; Godfrey, Michael J. ; Lennon, Ryan J. ; Ryan, James L. ; Bresnahan, John F. ; Rihal, Charanjit S. ; Ting, Henry H. / Initial experience with the Cardiva Boomerang™ vascular closure device in diagnostic catherization. In: Catheterization and Cardiovascular Interventions. 2007 ; Vol. 69, No. 2. pp. 203-208.
@article{6b2b94bee54849bdbe465227787fc747,
title = "Initial experience with the Cardiva Boomerang™ vascular closure device in diagnostic catherization",
abstract = "Objectives: The authors studied the safety and efficacy of the Cardiva Boomerang™ vascular closure device in patients undergoing diagnostic cardiac catheterization. Background: Conventional vascular closure devices (sutures, collagen plugs, or metal clips) have been associated with catastrophic complications including arterial occlusion and foreign body infections; furthermore, they cannot be utilized in patients with peripheral vascular disease or vascular access site in a vessel other than the common femoral artery. The Cardiva Boomerang™ device facilitates vascular hemostasis without leaving any foreign body behind at the access site, can be used in peripheral vascular disease, and can be used in vessels other than the common femoral artery. Methods: A total of 96 patients undergoing transfemoral diagnostic cardiac catheterization were included in this study, including 25 (26{\%}) patients with contraindications to conventional closure devices. Femoral angiography was performed prior to deployment of the Cardiva Boomerang™ closure device. Patients were ambulated at 1 hr after hemostasis was achieved. Results: The device was successfully deployed and hemostasis achieved with the device alone in 95 (99{\%}) patients. The device failed to deploy in 1 (1{\%}) patient and required conversion to standard manual compression. Minor complications were observed in 5 (5{\%}) patients. No patients experienced major complications including femoral hematoma > 4 cm, red blood cell transfusion, retroperitoneal bleed, arteriovenous fistula, pseudoaneurysm, infection, arterial occlusion, or vascular surgery. Conclusions: The Cardiva Boomerang™ device is safe and effective in patients undergoing diagnostic cardiac catheterization using the transfemoral approach, facilitating early ambulation with low rates of vascular complications.",
keywords = "Cardiac catheterization, Closure device, Vascular access",
author = "Doyle, {Brendan J.} and Godfrey, {Michael J.} and Lennon, {Ryan J.} and Ryan, {James L.} and Bresnahan, {John F.} and Rihal, {Charanjit S.} and Ting, {Henry H.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1002/ccd.20937",
language = "English (US)",
volume = "69",
pages = "203--208",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Initial experience with the Cardiva Boomerang™ vascular closure device in diagnostic catherization

AU - Doyle, Brendan J.

AU - Godfrey, Michael J.

AU - Lennon, Ryan J.

AU - Ryan, James L.

AU - Bresnahan, John F.

AU - Rihal, Charanjit S.

AU - Ting, Henry H.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Objectives: The authors studied the safety and efficacy of the Cardiva Boomerang™ vascular closure device in patients undergoing diagnostic cardiac catheterization. Background: Conventional vascular closure devices (sutures, collagen plugs, or metal clips) have been associated with catastrophic complications including arterial occlusion and foreign body infections; furthermore, they cannot be utilized in patients with peripheral vascular disease or vascular access site in a vessel other than the common femoral artery. The Cardiva Boomerang™ device facilitates vascular hemostasis without leaving any foreign body behind at the access site, can be used in peripheral vascular disease, and can be used in vessels other than the common femoral artery. Methods: A total of 96 patients undergoing transfemoral diagnostic cardiac catheterization were included in this study, including 25 (26%) patients with contraindications to conventional closure devices. Femoral angiography was performed prior to deployment of the Cardiva Boomerang™ closure device. Patients were ambulated at 1 hr after hemostasis was achieved. Results: The device was successfully deployed and hemostasis achieved with the device alone in 95 (99%) patients. The device failed to deploy in 1 (1%) patient and required conversion to standard manual compression. Minor complications were observed in 5 (5%) patients. No patients experienced major complications including femoral hematoma > 4 cm, red blood cell transfusion, retroperitoneal bleed, arteriovenous fistula, pseudoaneurysm, infection, arterial occlusion, or vascular surgery. Conclusions: The Cardiva Boomerang™ device is safe and effective in patients undergoing diagnostic cardiac catheterization using the transfemoral approach, facilitating early ambulation with low rates of vascular complications.

AB - Objectives: The authors studied the safety and efficacy of the Cardiva Boomerang™ vascular closure device in patients undergoing diagnostic cardiac catheterization. Background: Conventional vascular closure devices (sutures, collagen plugs, or metal clips) have been associated with catastrophic complications including arterial occlusion and foreign body infections; furthermore, they cannot be utilized in patients with peripheral vascular disease or vascular access site in a vessel other than the common femoral artery. The Cardiva Boomerang™ device facilitates vascular hemostasis without leaving any foreign body behind at the access site, can be used in peripheral vascular disease, and can be used in vessels other than the common femoral artery. Methods: A total of 96 patients undergoing transfemoral diagnostic cardiac catheterization were included in this study, including 25 (26%) patients with contraindications to conventional closure devices. Femoral angiography was performed prior to deployment of the Cardiva Boomerang™ closure device. Patients were ambulated at 1 hr after hemostasis was achieved. Results: The device was successfully deployed and hemostasis achieved with the device alone in 95 (99%) patients. The device failed to deploy in 1 (1%) patient and required conversion to standard manual compression. Minor complications were observed in 5 (5%) patients. No patients experienced major complications including femoral hematoma > 4 cm, red blood cell transfusion, retroperitoneal bleed, arteriovenous fistula, pseudoaneurysm, infection, arterial occlusion, or vascular surgery. Conclusions: The Cardiva Boomerang™ device is safe and effective in patients undergoing diagnostic cardiac catheterization using the transfemoral approach, facilitating early ambulation with low rates of vascular complications.

KW - Cardiac catheterization

KW - Closure device

KW - Vascular access

UR - http://www.scopus.com/inward/record.url?scp=33846796164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846796164&partnerID=8YFLogxK

U2 - 10.1002/ccd.20937

DO - 10.1002/ccd.20937

M3 - Article

C2 - 17195965

AN - SCOPUS:33846796164

VL - 69

SP - 203

EP - 208

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 2

ER -